Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

被引：12

作者：

Su, Po-Lan ^{[1
]}

Lin, Chien-Yu ^{[1
]}

Chen, Yi-Lin ^{[2
]}

Chen, Wan-Li ^{[2
]}

Lin, Chien-Chung ^{[1
,3
,4
]}

Su, Wu-Chou ^{[3
,5
,6
,7
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan

[2] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan

[3] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Inst Clin Med, Coll Med, Tainan, Taiwan

[4] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan

[5] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol, Tainan, Taiwan

[6] Natl Cheng Kung Univ, Ctr Appl Nanomed, Tainan, Taiwan

[7] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol, 138 Shengli Rd, Tainan 704, Taiwan

来源：

JTO CLINICAL AND RESEARCH REPORTS | 2021年 / 2卷 / 08期

关键词：

BRAF K601E mutation; Adenocarcinoma; Dab-rafenib; Trametinib; Case report; TARGETED THERAPY; CANCER;

D O I：

10.1016/j.jtocrr.2021.100202

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC with a BRAF K601E mutation, a class II BRAF mutation, who had a durable response to targeted therapy with combined dabrafenib and trametinib.(c) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

引用

页数：4

共 7 条

[1] Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations [J].

Dankner, Matthew ;

Rose, April A. N. ;

Rajkumar, Shivshankari ;

Siegel, Peter M. ;

Watson, Ian R. .

ONCOGENE, 2018, 37 (24) :3183-3199

[2] Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort [J].

Gautschi, Oliver ;

Milia, Julie ;

Cabarrou, Bastien ;

Bluthgen, Marie-Virginia ;

Besse, Benjamin ;

Smit, Egbert F. ;

Wolf, Juergen ;

Peters, Solange ;

Frueh, Martin ;

Koeberle, Dieter ;

Oulkhouir, Youssouf ;

Schuler, Martin ;

Curioni-Fontecedro, Alessandra ;

Huret, Benjamin ;

Kerjouan, Mallorie ;

Michels, Sebastian ;

Pall, Georg ;

Rothschild, Sacha ;

Schmid-Bindert, Gerald ;

Scheffler, Matthias ;

Veillon, Remi ;

Wannesson, Luciano ;

Diebold, Joachim ;

Zalcman, Gerard ;

Filleron, Thomas ;

Mazieres, Julien .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (10) :1451-1457

[3] Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations [J].

Mazieres, J. ;

Cropet, C. ;

Montane, L. ;

Barlesi, F. ;

Souquet, P. J. ;

Quantin, X. ;

Dubos-Arvis, C. ;

Otto, J. ;

Favier, L. ;

Avrillon, V ;

Cadranel, J. ;

Moro-Sibilot, D. ;

Monnet, I ;

Westeel, V ;

Le Treut, J. ;

Brain, E. ;

Tredaniel, J. ;

Jaffro, M. ;

Collot, S. ;

Ferretti, G. R. ;

Tiffon, C. ;

Oukhatar, C. Mahier-Ait ;

Blay, J. Y. .

ANNALS OF ONCOLOGY, 2020, 31 (02) :289-294

[4] Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations [J].

Menzer, Christian ;

Menzies, Alexander M. ;

Carlino, Matteo S. ;

Reijers, Irene ;

Groen, Emma J. ;

Eigentler, Thomas ;

de Groot, Jan Willem B. ;

van der Veldt, Astrid A. M. ;

Johnson, Douglas B. ;

Meiss, Frank ;

Schlaak, Max ;

Schilling, Bastian ;

Westgeest, Hans M. ;

Gutzmer, Ralf ;

Pfoehler, Claudia ;

Meier, Friedegund ;

Zimmer, Lisa ;

Suijkerbuijk, Karijn P. M. ;

Haalck, Thomas ;

Thoms, Kai-Martin ;

Herbschleb, Karin ;

Leichsenring, Jonas ;

Menzer, Alexander ;

Kopp-Schneider, Annette ;

Long, Georgina V. ;

Kefford, Richard ;

Enk, Alexander ;

Blank, Christian U. ;

Hassel, Jessica C. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (33) :3142-+

[5] Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial [J].

Planchard, David ;

Smit, Egbert F. ;

Groen, Harry J. M. ;

Mazieres, Julien ;

Besse, Benjamin ;

Helland, Aslaug ;

Giannone, Vanessa ;

D'Amelio, Anthony M., Jr. ;

Zhang, Pingkuan ;

Mookerjee, Bijoyesh ;

Johnson, Bruce E. .

LANCET ONCOLOGY, 2017, 18 (10) :1307-1316

[6] Dabrafenib plus trametinib in BRAF K601E-mutant melanoma [J].

Rogiers, A. ;

Thomas, D. ;

Vander Borght, S. ;

van den Oord, J. J. ;

Bechter, O. ;

Dewaele, M. ;

Rambow, F. ;

Marine, J. -C. ;

Wolter, P. .

BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (02) :421-422

[7] Targeted Therapy in BRAF p.K601E-Driven NSCLC: Case Report and Literature Review [J].

Saalfeld, Felix C. ;

Wenzel, Carina ;

Aust, Daniela E. ;

Wermke, Martin .

JCO PRECISION ONCOLOGY, 2020, 4 :1163-1166

← 1 →